Evidence map›Paper›PMID 39952600›Full record

ArticleCancer letters2025

Selective removal of proteins and microvesicles ex vivo from blood of pancreatic cancer patients using bioengineered adsorption filters.

Richard T Waldron, Ruoxiang Wang, Stephanie N Shishido, Aurelia Lugea, Ahmed G Ibrahim, Jeremy Mason, Matthew Ayres, Sarah J Parker, Jennifer E Van Eyk, Simon K Lo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Richard T WaldronDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. Electronic address: Richard.waldron@cshs.org.
Ruoxiang WangDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Stephanie N ShishidoConvergent Science Institute for Cancer, Michelson Center, University of Southern California, Los Angeles, CA, 90089, USA.
Aurelia LugeaDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Ahmed G IbrahimSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Jeremy MasonConvergent Science Institute for Cancer, Michelson Center, University of Southern California, Los Angeles, CA, 90089, USA; Institute of Urology, Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA; Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.
Matthew AyresSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Sarah J ParkerSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Jennifer E Van EykSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Simon K LoDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Peter KuhnConvergent Science Institute for Cancer, Michelson Center, University of Southern California, Los Angeles, CA, 90089, USA; Institute of Urology, Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA; Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA; Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA, 90089, USA; Department of Aerospace and Mechanical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA, 90089, USA; Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, CA, 90089, USA.
Stephen J PandolDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
The paradoxical roles of beta hydroxy butyrate in the liver pro-metastatic nicheP01CA233452 · NCI · CEDARS-SINAI MEDICAL CENTER · PI BHOWMICK, NEIL A., LU, SHELLY CHI-LOO · 2020 to 2024
$9.5M
Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes - Administrative SupplementU01DK108314 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI Mark Goodarzi, Stephen J. Pandol · 2015 to 2026
$6.1M
Project 3: Role of the pancreatic fibroinflammatory microenvironment in obesity-promoted pancreatic cancerP01CA236585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EIBL, GUIDO ERWIN MICHAEL · 2020 to 2024
$5.6M
Multi-modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple MyelomaU01CA285013 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KUHN, PETER · 2023 to 2025
$3.4M
Macrophages as effectors of cell therapy for heart failureR01HL142579 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI IBRAHIM, AHMED · 2019 to 2023
$2.1M
Device for Preservation of Cell Free RNA in SalivaR21CA258013 · NCI · PRIME GENOMICS, INC. · PI NAUTIYAL, SHIVANI · 2021 to 2022
$460k
NCI NIH HHS P01 CA233452NCI NIH HHS P01 CA236585NCI NIH HHS P30 CA014089NCI NIH HHS R21 CA258013NCI NIH HHS U01 CA285013NHLBI NIH HHS R01 HL142579NIDDK NIH HHS U01 DK108314
6 · The paper itself

Abstract

Metastatic pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with limited efficacious therapeutic options. Recent investigations have provided proof of concept that circulating tumor cells (CTCs) are reduced by purification of PDAC patient blood samples through ExThera Seraph100™ adsorption filters. Whether additional tumorigenic factors are also removed remains inadequately studied. Here, matched whole blood and purified blood samples from seven PDAC patients were analyzed for microparticle and soluble protein content. For microparticle analysis, patient samples were stratified by abundance. Filters markedly reduced ∼200-nm particles when in high abundance. Exosomes, or vesicles ranging from ∼50 to 150-nm were not significantly affected by the purification process. Proteomic analysis of plasma from the whole and purified blood revealed only a limited number of differentially expressed proteins. The complement C1Q proteins were reduced by the purification process, likely due to their heparin binding affinity. In contrast, there was an elevation in cytoplasmic proteins after purification, which may be due to cell destruction. Taken together, this study shows the selective removal of a subfraction of larger (>200 nm) microvesicles and C1Q during blood purification by the Seraph100™. The clinical significance of these findings requires further study.

Indexed as

Blood ProteinsCarcinoma, Pancreatic DuctalCell-Derived MicroparticlesNeoplastic Cells, CirculatingPancreatic NeoplasmsAdsorptionAgedBioengineeringExosomesFemaleFiltrationHumansMaleMiddle AgedProteomicsBlood ProteinsComplement C1Q proteinMicrovesiclesPancreatic ductal adenocarcinomaQuantitative proteomic analysis

Identifiers

PMID39952600
PMCPMC12010918

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.